LAG-3 (human), mAb (11E3)



ALX-804-805-C100	100 µg	417.00 USD

Product Specification

Alternative Name:	Lymphocyte activation gene-3, FDC protein, CD223

Concentration:	0.5mg/ml

Purity:	≥95% (SDS-PAGE)

Formulation:	Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.

Clone:	11E3

Isotype:	Mouse IgG1

Immunogen:	Recombinant human LAG-3 (lymphocyte activation gene-3).

Source/Host:	Purified from concentrated hybridoma tissue culture supernatant by Protein A Sepharose™ CL-4B Flow Fast Column.

Specificity:	Recognizes the first N-terminal D1 domain of human and monkey LAG-3.

Application:	ELISA (capture) Immunocytochemistry Immunohistochemistry (frozen sections) Immunoprecipitation (10µg/ml) Western Blot (5µg/ml) Functional Application: Inhibition

Short Term Storage:	+4°C

Long Term Storage:	-20°C

Handling:	Avoid freeze/thaw cycles.

Miscellaneous/General:	Lymphocyte activation gene 3 (LAG-3, CD223) plays an important role in negatively regulating T cell proliferation, function, and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell coreceptor CD4, and binds to MHC class II molecules but with a significantly higher affinity than CD4.

Background / Technical Information:	SEPHAROSE is a trademark of GE Healthcare companies.

Product Literature References

A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett. 235, 147 (2006), Abstract;

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS 94, 5744 (1997), Abstract; Full Text

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics 39, 213 (1994), Abstract;